Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution
October 18, 2021 07:30 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Children in Latest Clinical Study Show Significant Reduction of Tooth Decay After Treatment with Vivos Guides
October 13, 2021 07:30 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company’s Technology for Obstructive Sleep Apnea
September 23, 2021 07:30 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics to Participate at the Benzinga Healthcare Small Cap Conference
September 22, 2021 07:30 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 07:30 ET
|
Vivos Therapeutics, Inc
Vivos management to present at 7:00 am EDT on September 13, 2021 HIGHLANDS RANCH, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical...
Vivos Therapeutics and Empower Sleep Launch Cooperative Relationship Aimed at Significantly Improving Proper Obstructive Sleep Apnea Diagnosis and Treatment
August 26, 2021 07:30 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
FDA Grants 510(k) Market Clearance to Vivos Therapeutics’ mmRNA Oral Appliance for Treating Mild to Moderate Sleep Apnea
August 23, 2021 07:30 ET
|
Vivos Therapeutics, Inc
Part of the Vivos System Treatment, the mmRNA Device Represents a Highly Effective Non-Surgical, Non-Invasive and Non-Pharmaceutical Alternative for Patients Suffering from OSA Approval Expands...
Detailed Summary of Study Reporting that One in Four Patients Show No Symptoms of Obstructive Sleep Apnea After Vivos Treatment Now Available on Vivos Therapeutics Website
August 17, 2021 16:05 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Reports Second Quarter 2021 Financial Results and Operational Update
August 12, 2021 16:05 ET
|
Vivos Therapeutics, Inc
Second Quarter Revenue Increased Over 37% Year-Over-Year and 30% Over Q1 2021 Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., Aug. 12, 2021 ...
Vivos Therapeutics to Participate at the Q3 Virtual Investor Summit
August 09, 2021 16:05 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative...